FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 751 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR 5-Year-Old Boy Battling Cancer Receives Dream Come True, Sworn In As... March 24, 2021 FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour November 26, 2021 Women Experience More Side Effects from Pelvic Radiation than Realized April 8, 2020 EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) June 1, 2023 Load more HOT NEWS Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix What Is Mindfulness and How Can It Help People With Cancer? 3 ways we’re helping teenagers and young adults with cancer Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with...
